Abstracts Archive - Page 545 of 1683 - ATC Abstracts

2020 American Transplant Congress
Living Donor Gender Disparities Vary by Donor-Recipient Familial Relationship
Y. Chen¹, Y. Hung², C. de Crescenzo¹, C. Rickert¹, Y. Hsu³, H. Yeh¹, D. Chang¹
¹Department of Surgery, Massachusetts General Hospital, Boston, MA, ²Department of Surgery, Sinai Hospital of Baltimore, Baltimore, MA, ³Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA
*Purpose: Women are more likely to be living transplant donors and less likely to be recipients. It has been difficult to distinguish how much of…
2020 American Transplant Congress
The Impact of Purposeful Reductions in Immunosuppression on Clinical Outcomes in Kidney Transplantation
K. Foster, H. Perkins, N. Patel, C. Perez, N. Pilch, H. Meadows, F. Bartlett, V. Rao, M. Casey, M. Posadas Salas, K. Soliman, J. McGillicuddy, D. Taber
MUSC Health, Charleston, SC
*Purpose: Reductions to immunosuppressive therapy (IS) are often made due to infection or other IS intolerances, but little is known of impact of these reductions…
2020 American Transplant Congress
Infectious Complications and Malignancy after Kidney Transplantation in the Elderly Population
L. Liriano-Ward, M. Parides, Y. Al Azzi, C. Pynadath, M. Ajaimy, J. Graham, S. Greenstein, M. Kinkhabwala, J. Rocca, E. Akalin
Montefiore Medical Center, Bronx, NY
*Purpose: Kidney transplantation improves quality of life and survival in all patients regardless of age. However, older patients are prone to development of side effects…
2020 American Transplant Congress
Improved Outcomes Over the Past 13 Years in HIV Positive Kidney Transplant Recipients-A Single Center Experience
A. Mattiazzi¹, J. F. Camargo², S. Anjan², M. I. Morris², L. Abbo², J. Simkins², Y. Natori², K. Aoke³, A. Zilli³, R. Thurston³, M. Muldoon³, L. Preczewski³, L. J. Chen⁴, G. W. Burke⁴, G. Ciancio⁴, G. Guerra¹
¹Medicine. Division of Nephrology, University of Miami/Miami Transplant Institute, Miami, FL, ²Medine. Division of Infectious Disease, University of Miami/Miami Transplant Institute, Miami, FL, ³Miami Transplant Institute, Miami, FL, ⁴Surgery, University of Miami/Miami Transplant Institute, Miami, FL
*Purpose: Kidney transplantation in HIV positive recipients (HIV+) is the treatment of choice for renal failure in patients (P) who maintain CD4+ counts ≥ 200/mm3and…
2020 American Transplant Congress
Impact of Frailty on Early and Late Hospital Readmission after Kidney Transplantation
H. Hendra¹, B. Sandhu², E. Frackiewicz², G. Jones², P. Masson², R. Motallebzadeh³
¹Centre for Transplantation, Department of Renal Medicine, University College London & Royal Free London NHS Foundation Trust, London, United Kingdom, ²Royal Free Hospital, London, United Kingdom, ³Centre for Transplantation, University College London & Royal Free London NHS Foundation Trust, London, United Kingdom
*Purpose: Currently there are no tools to predict outcomes after kidney transplantation (KTx). This study assesses whether frailty influences post-KTx complications. Understanding frailty and its…
2020 American Transplant Congress
Change in the Willingness of Transplant Candidates to Accept Hepatitis C Virus Positive Deceased Donor Organs in the Era of Direct-Acting Antivirals
Q. Yuan, S. Hong, E. Roth, M. Sise, E. Bethea, W. Williams, H. Yeh, N. Elias
Transplant Center, Massachusetts General Hospital，Harvard Medical School, Boston, MA
*Purpose: Direct-acting antiviral (DAA) medications’ advent in 2014 very effectively changed the hepatitis C virus (HCV) treatment landscape and allowed post-transplant HCV therapy. We aimed…
2020 American Transplant Congress
Survey of Clinician Opinions on Use of Organ Transplants from Hepatitis C Virus Positive Donors: Identifying & Overcoming Barriers
K. Lentine¹, T. Alhamad², D. Peipert³, Y. Caliskan¹, B. Concepcion⁴, R. Forbes⁴, M. Schnitzler¹, Z. Zhang¹, S. Chang², M. Cooper⁵, R. Bloom⁶, R. Mannon⁷, D. Axelrod⁸
¹Saint Louis U, Saint Louis, MO, ²Washington U, Saint Louis, MO, ³Northwestern, Chicago, IL, ⁴Vanderbilt, Nashville, TN, ⁵Georgetown, Washington, DC, ⁶U Penn, Philadelphia, MO, ⁷UAB, Birmingham, AL, ⁸U Iowa, Iowa City, IA
*Purpose: Increasing the use of Hepatitis C Virus (HCV) viremic (Nucleic Acid Testing (NAT)+) donor organs for HCV uninfected (HCV-) patients is a potential approach…
2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
V. S. Potluri¹, F. Naqvi², P. Reese¹, M. Shah¹, D. Brown², S. Prenner¹, A. Loupy³, A. Woodards¹, P. Abt¹, E. Blumberg¹, J. Trofe-Clark¹, D. Segev², R. Bloom¹, D. Sawinski¹, C. Durand², P. Porrett¹, M. Levine¹, D. Goldberg⁴, N. Desai²
¹University of Pennsylvania, Philadelphia, PA, ²Johns Hopkins, Baltimore, MD, ³Paris Transplant Group, Paris, France, ⁴University of Miami, Miami, FL
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
H. Berry, J. Byrns, L. Crona, T. Capes, J. M. Steinbrink, E. K. Maziarz, C. R. Wolfe
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…
2020 American Transplant Congress
Patient Reported Medication Nonadherence and Tolerability: Results of a Prospective Observational Study
D. Taber, N. Patel, K. Foster, F. Bartlett, C. Perez, H. Meadows, N. Pilch, A. Posadas, K. Soliman, V. Rao, M. Casey, V. Rohan, J. McGillicuddy, S. Nadig, D. Dubay
MUSC, Charleston, SC
*Purpose: Medication nonadherence (MNA) is a major contributor to late allograft loss in transplantation (txp). Immunosuppression therapy is highly effective at preventing rejection yet presents…